Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like FDA Orders 6 Partial or Full Clinical Holds on Celgene's Blood Cancer Studies September 6, 2017 BioNTech Release: MammaTyper Enables More Precise Prediction Of The Response To Neoadjuvant Chemotherapy Compared To Manual Or Digitalized IHC February 14, 2017 Cambridge's Enumeral Filed for Bankruptcy, Sells Assets to Bay Area's XOMA February 6, 2018
BioNTech Release: MammaTyper Enables More Precise Prediction Of The Response To Neoadjuvant Chemotherapy Compared To Manual Or Digitalized IHC February 14, 2017
